Skip to content
AI IntelligenceMar 3, 2026Primary Market
Article

Antiverse · $9.3M · Series A

UK-based biotech company Antiverse has closed a $9.3 million Series A round. The company uses AI to design therapeutic antibodies for hard-to-target disease targets. The round was led by Soulmates Ventures.

Data Cube AI EditorialSource: Tech.eu
01

Source Brief

UK-based biotech company Antiverse has closed a $9.3 million Series A round. The company uses AI to design therapeutic antibodies for hard-to-target disease targets. The round was led by Soulmates Ventures.